Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 70INDUSTRY 64NETWORK 4OTHER_GOV 2NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Lymphoma 15Burkitt Lymphoma 8Neoplasms, Plasma Cell 5Hodgkin Disease 5Recurrence 4Leukemia, Biphenotypic, Acute 4Immunoglobulin Light-chain Amyloidosis 4Waldenstrom Macroglobulinemia 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Vomiting 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Smoldering Multiple Myeloma 1Seminoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1

Interventions

Vinorelbine 4Dexamethasone 4Filgrastim 3Vincristine 2Peripheral Blood Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fenretinide 2Etoposide 2Cytarabine 2Carmustine 2Bortezomib 2zanubrutinib 1relatlimab 1pomalidomide 1pegaspargase 1palbociclib 1liposomal amphotericin B 1ixazomib 1irinotecan sucrosofate 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1etoposide phosphate 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × Recurrence × Dexamethasone × Clear all
NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Multiple Myeloma Research Consortium

Phase 1/2 Terminated
14 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

SWOG Cancer Research Network

Phase 2 Completed
143 enrolled 14 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT01913730 2023-12-13

Maintenance Therapy With Subcutaneous Bortezomib

European Myeloma Network B.V.

Phase 2 Completed
63 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

European Society for Blood and Marrow Transplantation

Phase 3 Terminated
269 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡